Intermittent high-dose vitamin C therapy in patients with HTLV-I associated myelopathy.
Open accessAbstract
The efficacy of intermittent high-dose vitamin C therapy was evaluated in seven patients with HTLV-I-associated myelopathy (HAM). All HAM patients responded well to this therapy without serious side effects. Grade of disability score improved at 9.7 (SD 5.8) months after the therapy from 7.1 (3.3) to 3.6 (2.0) (p < 0.01). Serum immunosuppressive acidic protein was elevated before and decreased after the therapy from 747 (316) to 398 (86) micrograms/ml (p < 0.05), suggesting favourable immunomodulatory action of vitamin C therapy in HAM patients.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the same vitamin C trial, CSF HTLV-1 antibody titre remained unchanged throughout treatment.
“CSF HTLV-1 antibody titre remained unchanged throughout treatment.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [254]
In an open-label trial of vitamin C therapy in seven HAM patients, patients demonstrated significant improvements in motor function but reduced with treatment cessation.
“Patients demonstrated significant improvements in motor function but reduced with treatment cessation.”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [254]
Cited by
Sorted by citations
Therapeutic trials in 200 patients with HTLV-Iassociated myelopathy/tropical spastic paraparesis
Nakagawa, M., Nakahara, K., Maruyama, Y., Kawabata, M., Higuchi, I., Kubota, H., Izumo, S., Arimura, K., & Osame, M. (1996) · Journal of Neurovirology · doi:10.3109/13550289609146899 · Cited by 150 · see citing works
Lehky, T. J., Levin, M. C., Kubota, R., Bamford, R. N., Flerlage, A. N., Soldan, S. S., Leist, T. P., Xavier, A., White, J. D., Brown, M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410440613 · Cited by 80 · see citing works
Current State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22 · see citing works
“…Topical or systemic corticosteroids and mydriatics [263] HTLV-1-associated Sjögren’s Syndrome Artificial lubricants such as saliva/tears replacement solutions coupled with systemic pharmacotherapy with pilocarpine hydrochloride [264] HTLV-1-associated Hashimoto’s thyroiditis and Graves’ disease”
Background
- Authors
- Kataoka, A., Imai, H., Inayoshi, S., & Tsuda, T.
- Affiliations
- Oita University (JP)
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 1993-11-01
- Volume
- 56
- Issue
- 11
- Pages
- 1213-1216
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC489823
- OpenAlex
- W2169756625
- Cited by
- 39
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 1 · 2016: 1 · 2015: 2 · 2013: 1 · 2012: 1
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Vitamin C and Antioxidants Research
- Health Sciences › Medicine › Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- ascorbic acid therapy, tropical spastic paraparesis, immunosuppressive acidic protein, immunomodulation, disability score, treatment efficacy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Ascorbic Acid, Brain, Evoked Potentials, Somatosensory, Female, Humans, Male, Middle Aged, Neoplasm Proteins, HTLV-I Antibodies, Paraparesis, Tropical Spastic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
